Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Akumin Inc
AKUMQ
Healthcare
Akumin Inc. is a provider of radiology and oncology services to health systems, hospitals, physician groups, and patients all across the country. The Company operates through two segments: Radiology and Oncology. The Company provides fixed-site outpatient diagnostic imaging services through a network of approximately 180 owned and/or operated imaging locations, and outpatient radiology and...
oncology services and solutions to approximately 1,000 hospitals and health systems across 48 states. Its imaging procedures include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography and other related procedures. Its cancer care services include a full suite of radiation therapy and related offerings. Its services include radiology exams, radiology technology, radiology subspecialties, oncology conditions treated and oncology radiation therapy.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
OTCPK:AKUMQ - Post Discussion
Akumin Inc
> There’s a ton of upside to Akumin (AKU), says Clarus
New Post
View:
Discussion
List
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Aug 16, 2022 6:35pm
There’s a ton of upside to Akumin (AKU), says Clarus
By Jayson MacLean
Published on August 16, 2022
It’s a good time to be buying US healthcare stock Akumin Inc. (NASDAQ:AKU), according to Clarus Securities analyst Noel Atkinson. Akumin is down about 68 per cent over the past 12 months, but a new cash injection has Atkinson raising his target price on Monday from $6.50 to $6.75 per share, good for a projected return of 777 per cent at the time of publication.
Continue reading at link below:
https://www.cantechletter.com/2022/08/theres-a-ton-of-upside-to-akumin-says-clarus/
(73)
•••
willyk3
X
View Profile
View Bullboard History
Comment by
willyk3
on Aug 16, 2022 7:04pm
Thanks for posting...we need all the good press we can get.
(113)
•••
mjh9413
X
View Profile
View Bullboard History
Comment by
mjh9413
on Aug 25, 2022 12:07am
I bought because I liked the idea the Alliance people were going to steer the Company but with Zine and Stonepeak holding sway I am peeved. Zine gets a nice paycheck and other benefits while stonepeak reaps Millions$ in finance charges every qtr, the latter inflating the adj Ebitda number by 80%+. The latter wud have prevailed under any leadership but the existing group is just 'for the
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >